Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics researchJune 11, 2025
Share Facebook Twitter LinkedIn Pinterest Email Tony Zhang, OptionsPlay chief strategist, joins ‘Power Lunch’ to discuss earnings and valuations for JPMorgan and his bearish case for the stock.